IRMD Stock Analysis: Buy, Sell, or Hold?
IRMD - iRadimed Corporation
$95.41
-1.95 (-2.00%)
▼
5d:
-3.82%
30d:
-7.84%
90d:
-2.09%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 04, 2026
Get Alerted When IRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IRMD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: IRMD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$84.11
Based on 7.8% avg growth
INTRINSIC VALUE TODAY
$52.23
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRMD is currently trading at $95.41, which is considered oversold relative to its 30-day fair value range of $98.53 to $102.82. The stock's valuation (Forward PE: 42.0) is in line with its historical norms (44.7). Remarkably, the market is currently pricing in an annual earnings decline of 2.1% over the next few years. This pessimistic expectation contrasts with the company's recent 24.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRMD is showing support break momentum. The price is currently testing key support at $95.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $120.00 (+23.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRMD is showing support break momentum. The price is currently testing key support at $95.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $120.00 (+23.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$98.53 -
$102.82
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.3% below Wall St target ($120.00)
Fair Price Analysis
30-Day Fair Range
$98.53 -
$102.82
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$4.20
(4.4%)
Support & Resistance Levels
Support Level
$95.26
Resistance Level
$103.65
Current Trend
Support Break
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
41.97
Wall Street Target
$120.00
(+23.3%)
Revenue Growth (YoY)
17.0%
Earnings Growth (YoY)
24.8%
Profit Margin
26.8%
Valuation Discount vs History
-2.1% cheaper
PE vs Historical
42.0 vs 44.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.1%
(market-implied from PE analysis)
1-Year Target
$95.32
(-2%)
2-Year Target
$93.31
(-4%)
3-Year Target
$91.35
(-6%)
3-Yr Target (if PE normalizes)
(PE: 42→45)
$97.31
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 42.0, Growth: 11.5%)
$135.10
(+39%)
Base:
(SPY PE: 22.4, Growth: 11.5%)
$72.11
(-26%)
Bear:
(PE: 19.0, Growth: 11.5%)
$61.30
(-37%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (57x PE), but valuation improves significantly next year (42x PE) as earnings recover.
Trailing PE: 56.86 | Current EPS (TTM): $1.75
Bull Case
$145.10
(+46%)
Analyst growth 32.6%, PE expands to 62.5
Base Case
$131.91
(+33%)
Market implied 32.6%, PE stable at 56.9
Bear Case
$67.66
(-32%)
Severe decline -20.0%, PE contracts to 48.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 42.0 to 44.7
Stabilization Target:
$103.70
(+6.5%)
PE Expansion Potential:
+6.5%
Share & Embed Analysis
Last updated: March 30, 2026 10:26 AM ET
Data refreshes hourly during market hours. Next update: 11:26 AM
Data refreshes hourly during market hours. Next update: 11:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Roger E Susi
SELL
2500 shares
2026-03-17
Roger E Susi
SELL
5000 shares
2026-03-16
Roger E Susi
SELL
2500 shares
2026-03-10
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 56 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 58 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$96 | 53 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$93 | 58 HOLD |
|
PEN
Penumbra Inc |
STRONG BUY
18 analysts |
$360 | 56 HOLD |
Advanced IRMD Option Strategies
Professional options setups generated by AI based on today's IRMD price and gamma walls.
